Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.

Also called NCT02143765

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 248 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02143765
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02143765. Randomized; no masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2015-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus
Acronym
Match-101
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Mitiglinide
Intervention (Drug)
Acarbose
Lead sponsor
Zhongda Hospital (class: other)

Record details

Record id
cardio:ct-nct02143765
Content hash
3bfe1b0d021e14e179f58d6963a32260a1ff9afead66b23288fd8eb006030ac5